Melanocortin-1 receptor (MC1R) plays a key role in skin pigmentation, and its variants are linked with a higher melanoma risk. The influence of MC1R variants on the outcomes of patients with metastatic melanoma (MM) treated with BRAF inhibitors (BRAFi) is unknown. We studied the MC1R status in a cohort of 53 consecutive BRAF-mutated patients with MM treated with BRAFi. We also evaluated the effect of vemurafenib in four V600BRAF melanoma cell lines with/without MC1R variants. We found a significant correlation between the presence of MC1R variants and worse outcomes in terms of both overall response rate (ORR; 59% versus 95%, P = 0.011 univariate, P = 0.028 multivariate analysis) and progression-free survival (PFS) shorter than 6 months (72% versus 33%, P = 0.012 univariate, P = 0.027 multivariate analysis). No difference in overall survival (OS) was reported, probably due to subsequent treatments. Data in vitro showed a significant different phosphorylation of Erk1/2 and p38 MAPK during treatment, associated with a greater increase in vemurafenib IC50 in MC1R variant cell lines.
Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors / Guida, M.; Strippoli, S.; Ferretta, A.; Bartolomeo, N.; Porcelli, L.; Maida, I.; Azzariti, A.; Tommasi, S.; Grieco, C.; Guida, S.; Albano, A.; Lorusso, V.; Guida, G.. - In: PIGMENT CELL & MELANOMA RESEARCH. - ISSN 1755-1471. - 29:6(2016), pp. 679-687.
Data di pubblicazione: | 2016 |
Titolo: | Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors |
Autore/i: | Guida, M.; Strippoli, S.; Ferretta, A.; Bartolomeo, N.; Porcelli, L.; Maida, I.; Azzariti, A.; Tommasi, S.; Grieco, C.; Guida, S.; Albano, A.; Lorusso, V.; Guida, G. |
Autore/i UNIMORE: | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.1111/pcmr.12516 |
Rivista: | |
Volume: | 29 |
Fascicolo: | 6 |
Pagina iniziale: | 679 |
Pagina finale: | 687 |
Codice identificativo ISI: | WOS:000388312900010 |
Codice identificativo Scopus: | 2-s2.0-84995543251 |
Codice identificativo Pubmed: | 27540956 |
Citazione: | Detrimental effects of melanocortin-1 receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors / Guida, M.; Strippoli, S.; Ferretta, A.; Bartolomeo, N.; Porcelli, L.; Maida, I.; Azzariti, A.; Tommasi, S.; Grieco, C.; Guida, S.; Albano, A.; Lorusso, V.; Guida, G.. - In: PIGMENT CELL & MELANOMA RESEARCH. - ISSN 1755-1471. - 29:6(2016), pp. 679-687. |
Tipologia | Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
pcmr.12516.pdf | Versione dell'editore (versione pubblicata) | Administrator Richiedi una copia |

I documenti presenti in Iris Unimore sono rilasciati con licenza Creative Commons Attribuzione - Non commerciale - Non opere derivate 3.0 Italia, salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris